ACADIA PHARMACEUTICALS INC

Drug pipeline (3)

Asset	Stage	Revenue	Trials	Status
NUPLAZID	approved	$183.1MQ2 2026	8	approved
DAYBUE	approved	$124.8MQ2 2026	4	approved
DAYBUE STIX	approved	—	4	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (39)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT03575052	phase3	completed	2018-05-21	2022-05-06	ACADIA Pharmaceuticals Inc.	A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
NCT03118947	phase2	completed	2017-02-23	2019-02-25	ACADIA Pharmaceuticals Inc.	A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
NCT00658567	phase3	completed	2008-03-01	2009-12-01	ACADIA Pharmaceuticals Inc.	A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
NCT00477672	phase3	completed	2007-06-01	2009-06-01	ACADIA Pharmaceuticals Inc.	A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
NCT02035553	phase2	completed	2013-11-01	2016-09-28	ACADIA Pharmaceuticals Inc.	A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis

FDA applications (4)

Application

Approved

Type

Applicant

Products

NDA 219884

2025-12-11

NDA

ACADIA PHARMACEUTICALS INC

NDA 217026

2023-03-10

NDA

ACADIA PHARMACEUTICALS INC

NDA 210793

2018-06-28

NDA

ACADIA PHARMACEUTICALS INC

NDA 207318

2016-04-29

NDA

ACADIA PHARMACEUTICALS INC